FDA Inspection 1175790 — Centrient Pharmaceuticals India Private Limited
The FDA completed an inspection of Centrient Pharmaceuticals India Private Limited on July 1, 2022 in Nawashahr. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- July 1, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Nawashahr (India)